Esopam 10

Escitalopram oxalate

Major depressive episodes, panic disorders w/ or w/o agoraphobia, social & generalized anxiety disorder, obsessive-compulsive disorder (OCD).

Major depressive episodes, social & generalized anxiety disorder, OCD 10 mg once daily, may be increased to max: 20 mg daily. Panic disorder w/ or w/o agoraphobia Initially 5 mg for 1st wk before increasing to 10 mg daily. May be further increased to max: 20 mg daily. Elderly >65 yr Initially ½ the usual dose. Reduce hepatic function, patient known to be poor CYP2C19 metabolizer Initially 5 mg daily for 1st 2 wk, may be increased to 10 mg daily.

May be taken with or without food.

Hypersensitivity. Patients w/ known QT interval prolongation or congenital long QT syndrome. Concomitant treatment w/ nonselective, irreversible MAOIs; reversible MAO-A inhibitors eg, moclobemide or reversible nonselective MAOI eg, linezolid; medicinal products prolonging QT interval.

Discontinue use if serotonin syndrome or increased seizure frequency occurs. Avoid use in patients w/ unstable epilepsy. Monitor for clinical worsening, suicidal behaviour or thoughts & unusual changes in behaviour. Paradoxical anxiety; history of mania/hypomania; diabetes; akathisia/psychomotor restlessness; sexual dysfunction; CHD; significant bradycardia, recent acute MI or uncompensated heart failure; known bleeding tendencies; angle-closure glaucoma or history of glaucoma. Correct electrolyte disturbances prior to treatment. Closely monitor patients w/ controlled epilepsy. May cause serious allergic-type reactions due to Na metabisulfite. Avoid abrupt discontinuation. Concomitant use w/ drugs causing hyponatraemia; oral anticoagulants, medicinal products affecting platelet function eg, atypical antipsychotics, phenothiazines, TCAs, ASA, NSAIDs, ticlopidine, dipyridamole; medicinal products w/ serotonergic effects eg, sumatriptan or other triptans, tramadol, tryptophan; St. John's wort; electroconvulsive therapy. Cirrhotic patients. Severe renal impairment (CrCl <30 mL/min). Not to be used during pregnancy. Not recommended during lactation. Not to be used in childn & adolescents <18 yr; suicide-related behaviours & hostility in childn & adolescents. Elderly.

Headache; nausea. Decreased/increased appetite; increased wt; anxiety, restlessness, abnormal dreams, decreased libido, female anorgasmia; insomnia, somnolence, dizziness, paraesthesia, tremor; sinusitis, yawning; diarrhea, constipation, vomiting, dry mouth; increased sweating; arthralgia, myalgia; ejaculation disorder, male impotence; fatigue, pyrexia.

Serotonin syndrome w/ irreversible nonselective MAOIs; reversible selective MAO-A inhibitor eg, moclobemide; reversible nonselective MAOI eg, linezolid; irreversible selective MAO-B inhibitor eg, selegiline; serotonergic medicinal products eg, tramadol, sumatriptan, other triptans; medicinal products lowering seizure threshold eg, TCAs, SSRIs, neuroleptics (eg, phenothiazines, thioxanthenes, butyrophenones), mefloquine, bupropion, tramadol. Enhanced effects w/ lithium, tryptophan. Increased AR incidence w/ St. John's wort. Altered anticoagulant effect w/ oral anticoagulants. Increased bleeding tendencies w/ NSAIDs. Increased risk of malignant arrhythmias w/ hypokalaemia-hypomagnesaemia-inducing medicinal products. Increased plasma conc w/ omeprazole, cimetidine. Medicinal products prolonging QT interval eg, class IA & III antiarrhythmics; antipsychotics eg, phenothiazine derivatives, pimozide, haloperidol; TCAs; certain antimicrobial agents eg, sparfloxacin, moxifloxacin, erythromycin IV, pentamidine, halofantrine; certain antihistamines eg, astemizole, mizolastine; CYP2C19 inhibitors eg, esomeprazole, fluconazole, fluvoxamine, lansoprazole, ticlopidine; CYP2D6-metabolized drugs eg, flecainide, propafenone, metoprolol, desipramine, clomipramine, nortriptyline, risperidone, thioridazine. Not to be combined w/ alcohol.

Antidepressants

N06AB10 - escitalopram ; Belongs to the class of selective serotonin reuptake inhibitors. Used in the management of depression.

B